

Cancer statistics: Breast cancer in situ

Ca-A Cancer Journal for Clinicians

65, 481-495

DOI: [10.3322/caac.21321](https://doi.org/10.3322/caac.21321)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Risk factors and biomarkers of life-threatening cancers. <i>Ecancermedicalsecience</i> , 2015, 9, 596.	0.6	6
2	Substance P Receptor Signaling Mediates Doxorubicin-Induced Cardiomyocyte Apoptosis and Triple-Negative Breast Cancer Chemoresistance. <i>BioMed Research International</i> , 2016, 2016, 1-9.	0.9	48
3	KAEMPFEROL, A FLAVONOID COMPOUND FROM GYNURA MEDICA INDUCED APOPTOSIS AND GROWTH INHIBITION IN MCF-7 BREAST CANCER CELL. <i>Tropical Journal of Obstetrics and Gynaecology</i> , 2016, 13, 210-215.	0.3	70
4	Automated detection of breast cancer lesions using adaptive thresholding and morphological operation. , 2016, , .		8
5	Lobular breast cancer: Clinical, molecular and morphological characteristics. <i>Pathology Research and Practice</i> , 2016, 212, 583-597.	1.0	109
6	Is the false-positive rate in mammography in North America too high?. <i>British Journal of Radiology</i> , 2016, 89, 20160045.	1.0	30
7	An in-vivo study for targeted delivery of copper-organic complex to breast cancer using chitosan polymer nanoparticles. <i>Materials Science and Engineering C</i> , 2016, 68, 327-337.	3.8	56
9	Antibody-Guided In Vivo Imaging for Early Detection of Mammary Gland Tumors. <i>Translational Oncology</i> , 2016, 9, 295-305.	1.7	25
10	Microwave-Assisted Syntheses of Benzimidazole-Containing Selenadiazole Derivatives That Induce Cell-Cycle Arrest and Apoptosis in Human Breast Cancer Cells by Activation of the ROS/AKT Pathway. <i>ChemMedChem</i> , 2016, 11, 2339-2346.	1.6	29
11	Platycodin D, a metabolite of Platycodin grandiflorum, inhibits highly metastatic MDA-MB-231 breast cancer growth in vitro and in vivo by targeting the MDM2 oncogene. <i>Oncology Reports</i> , 2016, 36, 1447-1456.	1.2	33
12	Adjuvant Radiotherapy in Early-Stage Breast Cancer: Evidence-Based Options. <i>Annals of Surgical Oncology</i> , 2016, 23, 3880-3890.	0.7	16
13	Active Surveillance for DCIS: The Importance of Selection Criteria and Monitoring. <i>Annals of Surgical Oncology</i> , 2016, 23, 4134-4136.	0.7	19
14	Macrophage migration inhibitory factor promotes breast cancer metastasis via activation of HMGB1/TLR4/NF kappa B axis. <i>Cancer Letters</i> , 2016, 375, 245-255.	3.2	86
15	Detection of human breast cancer cells using a 2-deoxy-D-glucose-functionalized superparamagnetic iron oxide nanoparticles. <i>Cancer Biomarkers</i> , 2017, 18, 367-374.	0.8	13
16	Adjuvant therapy in patients with ductal carcinoma in situ of the breast: The Pandora's box. <i>Cancer Treatment Reviews</i> , 2017, 55, 1-9.	3.4	21
17	Splicing factor hnRNPA2B1 contributes to tumorigenic potential of breast cancer cells through STAT3 and ERK1/2 signaling pathway. <i>Tumor Biology</i> , 2017, 39, 101042831769431.	0.8	58
18	Early Detection and Screening for Breast Cancer. <i>Seminars in Oncology Nursing</i> , 2017, 33, 141-155.	0.7	145
19	PGC-1 alpha interacts with microRNA-217 to functionally regulate breast cancer cell proliferation. <i>Biomedicine and Pharmacotherapy</i> , 2017, 85, 541-548.	2.5	23

#	ARTICLE	IF	CITATIONS
20	Leptin promotes the migration and invasion of breast cancer cells by upregulating ACAT2. <i>Cellular Oncology (Dordrecht)</i> , 2017, 40, 537-547.	2.1	54
21	Epidemiologic Risk Factors for In Situ and Invasive Breast Cancers Among Postmenopausal Women in the National Institutes of Health-AARP Diet and Health Study. <i>American Journal of Epidemiology</i> , 2017, 186, 1329-1340.	1.6	28
22	Severe fatigue after treatment of ductal carcinoma in situ: A comparison with age-matched breast cancer survivors and healthy controls. <i>Breast</i> , 2017, 31, 76-81.	0.9	11
23	Clinical Utility of the 12-Gene DCIS Score Assay: Impact on Radiotherapy Recommendations for Patients with Ductal Carcinoma In Situ. <i>Annals of Surgical Oncology</i> , 2017, 24, 660-668.	0.7	21
24	Ductal Carcinoma In Situ Biology, Biomarkers, and Diagnosis. <i>Frontiers in Oncology</i> , 2017, 7, 248.	1.3	88
25	[ARTICLE WITHDRAWN] miR-1193 Suppresses Proliferation and Invasion of Human Breast Cancer Cells Through Directly Targeting IGF2BP2. <i>Oncology Research</i> , 2017, 25, 579-585.	0.6	30
26	PTEN expression is upregulated by a RNA-binding protein RBM38 via enhancing its mRNA stability in breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 149.	3.5	47
27	Hypoxia-Induced TPM2 Methylation is Associated with Chemoresistance and Poor Prognosis in Breast Cancer. <i>Cellular Physiology and Biochemistry</i> , 2018, 45, 692-705.	1.1	41
28	OCA2 rs4778137 polymorphism predicts survival of breast cancer patients receiving neoadjuvant chemotherapy. <i>Gene</i> , 2018, 651, 161-165.	1.0	4
29	Pre-clinical study of a TNFR1-targeted 18F probe for PET imaging of breast cancer. <i>Amino Acids</i> , 2018, 50, 409-419.	1.2	10
30	Ductal Carcinoma in Situ of the Breast. , 2018, , 562-575.e4.		3
31	Anti-angiogenic effects of Qingdu granule on breast cancer through inhibiting NFAT signaling pathway. <i>Journal of Ethnopharmacology</i> , 2018, 222, 261-269.	2.0	13
32	Health-related quality of life and utility scores of patients with breast neoplasms in China: A multicenter cross-sectional survey. <i>Breast</i> , 2018, 39, 53-62.	0.9	25
33	Multifunctional nanoemulsions for intraductal delivery as a new platform for local treatment of breast cancer. <i>Drug Delivery</i> , 2018, 25, 654-667.	2.5	54
34	The Dana-Farber CISNET Model for Breast Cancer Screening Strategies: An Update. <i>Medical Decision Making</i> , 2018, 38, 44S-53S.	1.2	24
35	Carcinoma in situ of the breast in New South Wales, Australia: Current status and trends over the last 40 year. <i>Breast</i> , 2018, 37, 170-178.	0.9	10
36	A comprehensive analysis of polymorphic variants in steroid hormone and insulin-like growth factor-1 metabolism and risk of <i>in situ</i> breast cancer: Results from the Breast and Prostate Cancer Cohort Consortium. <i>International Journal of Cancer</i> , 2018, 142, 1182-1188.	2.3	0
37	Potent anti-proliferative activities of organochalcogenocyanates towards breast cancer. <i>Organic and Biomolecular Chemistry</i> , 2018, 16, 8769-8782.	1.5	19

#	ARTICLE	IF	CITATIONS
38	Epidemiology, Biology, Treatment, and Prevention of Ductal Carcinoma In Situ (DCIS). JNCI Cancer Spectrum, 2018, 2, pky063.	1.4	17
39	An Aptamer-Based Probe for Molecular Subtyping of Breast Cancer. Theranostics, 2018, 8, 5772-5783.	4.6	63
40	Long noncoding RNA ATB promotes the epithelial-mesenchymal transition by upregulating the miR-200c/Twist1 axis and predicts poor prognosis in breast cancer. Cell Death and Disease, 2018, 9, 1171.	2.7	59
41	Organotypic microfluidic breast cancer model reveals starvation-induced spatial-temporal metabolic adaptations. EBioMedicine, 2018, 37, 144-157.	2.7	68
42	Hypoxia-Inducible Factor 1 α Regulates the Transforming Growth Factor β 1/SMAD Family Member 3 Pathway to Promote Breast Cancer Progression. Journal of Breast Cancer, 2018, 21, 259.	0.8	31
43	Radiotherapy for Ductal Cancer In Situ (DCIS) of the Breast. , 2018, , 1-17.		0
44	Advances in Breast MRI in the Setting of Ductal Carcinoma In Situ. Seminars in Roentgenology, 2018, 53, 261-269.	0.2	5
45	LncRNA AWPPH promotes the growth of triple-negative breast cancer by up-regulating frizzled homolog 7 (FZD7). Bioscience Reports, 2018, 38, .	1.1	31
46	Long-term outcomes and prognostic analysis of percutaneous radiofrequency ablation in liver metastasis from breast cancer. International Journal of Hyperthermia, 2018, 35, 183-193.	1.1	30
47	Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patients. Scientific Reports, 2018, 8, 12974.	1.6	59
48	Ductal Carcinoma In Situ. Surgical Clinics of North America, 2018, 98, 725-745.	0.5	10
49	The Changing Paradigms for Breast Cancer Surgery: Performing Fewer and Less-Invasive Operations. Annals of Surgical Oncology, 2018, 25, 2807-2812.	0.7	13
50	MicroRNA-493 is a prognostic factor in triple-negative breast cancer. Cancer Science, 2018, 109, 2294-2301.	1.7	32
51	MiR-1301-3p inhibits human breast cancer cell proliferation by regulating cell cycle progression and apoptosis through directly targeting ICT1. Breast Cancer, 2018, 25, 742-752.	1.3	33
52	The effect of icotinib combined with chemotherapy in untreated non-small-cell lung cancer that harbored EGFR-sensitive mutations in a real-life setting: a retrospective analysis. OncoTargets and Therapy, 2018, Volume 11, 2345-2353.	1.0	9
53	Screening for Breast Cancer in 2018-What Should We be Doing Today?. Current Oncology, 2018, 25, 115-124.	0.9	152
54	Surgical management of ductal carcinoma in situ of the breast: A large retrospective study from a single institution. Breast Journal, 2019, 25, 1143-1153.	0.4	7
55	Ductal carcinoma in situ: to treat or not to treat, that is the question. British Journal of Cancer, 2019, 121, 285-292.	2.9	168

#	ARTICLE	IF	CITATIONS
56	Quantitative nuclear histomorphometric features are predictive of Oncotype DX risk categories in ductal carcinoma in situ: preliminary findings. <i>Breast Cancer Research</i> , 2019, 21, 114.	2.2	17
57	Depletion of mitochondrial protease OMA1 alters proliferative properties and promotes metastatic growth of breast cancer cells. <i>Scientific Reports</i> , 2019, 9, 14746.	1.6	18
58	Proposal for a Histological Staging System of Mammary Carcinomas in Dogs and Cats. Part 2: Feline Mammary Carcinomas. <i>Frontiers in Veterinary Science</i> , 2019, 6, 387.	0.9	16
60	Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2019, 37, 3152-3165.	0.8	117
61	Quantitative expression of MMPs 2, 9, 14, and collagen IV in LCIS and paired normal breast tissue. <i>Scientific Reports</i> , 2019, 9, 13432.	1.6	8
62	Use of Mastectomy for Overdiagnosed Breast Cancer in the United States: Analysis of the SEER 9 Cancer Registries. <i>Journal of Cancer Epidemiology</i> , 2019, 2019, 1-14.	0.5	8
63	Optimization of composition and obtainment parameters of biocompatible nanoemulsions intended for intraductal administration of piplartine (piperlongumine) and mammary tissue targeting. <i>International Journal of Pharmaceutics</i> , 2019, 567, 118460.	2.6	45
64	Incidence of Ductal Carcinoma <i>In Situ</i> in the United States, 2000–2014. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1316-1323.	1.1	22
65	Breast Ductal Carcinoma in Situ. <i>American Journal of Pathology</i> , 2019, 189, 942-945.	1.9	5
66	Caveolin-1: a multifaceted driver of breast cancer progression and its application in clinical treatment. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 1539-1552.	1.0	59
67	Management of Ductal Carcinoma In Situ (DCIS) of the Breast: Present Approaches and Future Directions. <i>Current Oncology Reports</i> , 2019, 21, 33.	1.8	31
68	Cancer Outcomes in DCIS Patients Without Locoregional Treatment. <i>Journal of the National Cancer Institute</i> , 2019, 111, 952-960.	3.0	76
69	Adherence to the World Cancer Research Fund/American Institute for Cancer Research cancer prevention recommendations and risk of in situ breast cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. <i>BMC Medicine</i> , 2019, 17, 221.	2.3	18
70	Estimating the magnitude of clinical benefit of local therapy in patients with DCIS. <i>Breast</i> , 2019, 48, S34-S38.	0.9	7
71	Med19 is involved in chemoresistance by mediating autophagy through HMGB1 in breast cancer. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 507-518.	1.2	25
72	Trends in lobular carcinoma in situ management: endocrine therapy use in California and New Jersey. <i>Cancer Causes and Control</i> , 2019, 30, 129-136.	0.8	1
73	Oncostatic treatment effect of triple negative breast cancer cell line with copper (I) nicotinate complex. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 4278-4290.	1.2	8
74	Increasing trends in in situ breast cancer incidence in a region with no population-based mammographic screening program: results from Zurich, Switzerland 2003–2014. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 653-660.	1.2	3

#	ARTICLE	IF	CITATIONS
75	Androgen Receptors in Resected Ductal Carcinoma In Situ of Breast: Novel Insights With Possible Implications for Testing and Targeted Endocrine Chemoprevention Trials. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 373-377.	0.6	3
76	Identification of miR-146a is Associated with the Aggressiveness and Suppresses Proliferation via Targeting CDKN2A in Breast Cancer. <i>Pathology and Oncology Research</i> , 2020, 26, 245-251.	0.9	7
77	Ductal Carcinoma in situ after Core Needle Biopsy: In Which Cases Is a Sentinel Node Biopsy Necessary?. <i>Breast Care</i> , 2020, 15, 260-264.	0.8	2
78	Association of lifestyle and clinical characteristics with receipt of radiotherapy treatment among women diagnosed with DCIS in the NIH-AARP Diet and Health Study. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 445-457.	1.1	1
79	Ductal Carcinoma in Situ: A French National Survey. Analysis of 2125 Patients. <i>Clinical Breast Cancer</i> , 2020, 20, e164-e172.	1.1	11
80	Immunohistochemistry for diagnosis and prognosis of breast cancer: a review. <i>Biotechnic and Histochemistry</i> , 2020, 95, 71-91.	0.7	57
81	Design and implementation of a new cable-driven robot for MRI-guided breast biopsy. <i>International Journal of Medical Robotics and Computer Assisted Surgery</i> , 2020, 16, e2063.	1.2	14
82	An improved random forest-based rule extraction method for breast cancer diagnosis. <i>Applied Soft Computing Journal</i> , 2020, 86, 105941.	4.1	79
83	N-Alkylisatin-Loaded Liposomes Target the Urokinase Plasminogen Activator System in Breast Cancer. <i>Pharmaceutics</i> , 2020, 12, 641.	2.0	11
84	Ratite oils for local transdermal therapy of 4-OH tamoxifen: development, characterization, and <i>in vivo</i> evaluation. <i>Journal of Liposome Research</i> , 2021, 31, 217-229.	1.5	9
85	Discrimination analysis of breast calcifications using <i>Cr</i> K-edge field radiography. <i>Medical Physics</i> , 2020, 47, 1813-1826.	1.6	12
86	Cytokine-induced killer cells-assisted tumor-targeting delivery of Her-2 monoclonal antibody-conjugated gold nanostars with NIR photosensitizer for enhanced therapy of cancer. <i>Journal of Materials Chemistry B</i> , 2020, 8, 8368-8382.	2.9	29
87	Macrophage migration inhibitory factor inhibition as a novel therapeutic approach against triple-negative breast cancer. <i>Cell Death and Disease</i> , 2020, 11, 774.	2.7	39
88	Efficacy of Emu Oil Transfersomes for Local Transdermal Delivery of 4-OH Tamoxifen in the Treatment of Breast Cancer. <i>Pharmaceutics</i> , 2020, 12, 807.	2.0	19
89	LncRNA SNHG3, a potential oncogene in human cancers. <i>Cancer Cell International</i> , 2020, 20, 536.	1.8	41
90	Functionalization of bismuth sulfide nanomaterials for their application in cancer theranostics. <i>Chinese Chemical Letters</i> , 2020, 31, 3015-3026.	4.8	20
91	Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer. <i>Cancer Reports</i> , 2020, 3, e1248.	0.6	5
92	Ductal Carcinoma In Situ of the Breast: Perspectives on Tumor Subtype and Treatment. <i>BioMed Research International</i> , 2020, 2020, 1-9.	0.9	3

#	ARTICLE	IF	CITATIONS
93	Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR. <i>Journal of Oncology</i> , 2020, 2020, 1-11.	0.6	125
94	De-Escalating Treatment of Low-Risk Breast Ductal Carcinoma In Situ. <i>Journal of Clinical Oncology</i> , 2020, 38, 1252-1254.	0.8	8
95	Loss of myoepithelial calponin characterizes high-risk ductal carcinoma in situ cases, which are further stratified by T cell composition. <i>Molecular Carcinogenesis</i> , 2020, 59, 701-712.	1.3	11
96	Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance). <i>Journal of Clinical Oncology</i> , 2020, 38, 1284-1292.	0.8	21
97	Dual Loading of Nanoparticles with Doxorubicin and Icotinib for the Synergistic Suppression of Non-Small Cell Lung Cancer. <i>International Journal of Medical Sciences</i> , 2020, 17, 390-402.	1.1	7
98	Saikosaponin D: A potential therapeutic drug for osteoarthritis. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2020, 14, 1175-1184.	1.3	18
99	Ductal Carcinoma In Situ Progression in Dog Model of Breast Cancer. <i>Cancers</i> , 2020, 12, 418.	1.7	13
100	Increased SIX1 expression promotes breast cancer metastasis by regulating lncATB-miR-200s-ZEB1 axis. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 5290-5303.	1.6	3
101	Design and control of a bionic needle puncture robot. <i>International Journal of Medical Robotics and Computer Assisted Surgery</i> , 2021, 17, e2200.	1.2	9
102	Circular RNA profiling facilitates the diagnosis and prognostic monitoring of breast cancer: A pairwise meta-analysis. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e23575.	0.9	8
103	HOXB5 promotes the progression of breast cancer through wnt/beta-catenin pathway. <i>Pathology Research and Practice</i> , 2021, 224, 153117.	1.0	11
104	Breast cancer, screening and diagnostic tools: All you need to know. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103174.	2.0	55
105	Comparison of the ductal carcinoma in situ between White Americans and Chinese Americans. <i>Medicine (United States)</i> , 2021, 100, e24136.	0.4	0
106	Association of variably methylated tumour DNA regions with overall survival for invasive lobular breast cancer. <i>Clinical Epigenetics</i> , 2021, 13, 11.	1.8	12
107	Clinicopathological Characteristics of Breast Ductal Carcinoma In Situ: An Analysis of Chinese Population of 617 Patients. <i>Journal of Oncology</i> , 2021, 2021, 1-6.	0.6	2
108	Variability in grading of ductal carcinoma <i>in situ</i> among an international group of pathologists. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 233-242.	1.3	16
109	Relationship of ITPKA expression with the prognosis of breast cancer. <i>Molecular Genetics & Genomic Medicine</i> , 2021, 9, e1598.	0.6	2
110	The Role of BRCA1/2-Mutated Tumor Microenvironment in Breast Cancer. <i>Cancers</i> , 2021, 13, 575.	1.7	8

#	ARTICLE	IF	CITATIONS
111	Risk for Invasive Cancers in Women With Breast Cancer In Situ: Results From a Population Not Covered by Organized Mammographic Screening. <i>Frontiers in Oncology</i> , 2021, 11, 606747.	1.3	2
112	Risk of hematologic malignancies after breast ductal carcinoma in situ treatment with ionizing radiation. <i>Npj Breast Cancer</i> , 2021, 7, 21.	2.3	0
113	Breast Cancer and the Other Non-Coding RNAs. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3280.	1.8	17
114	An Organotypic Mammary Duct Model Capturing Matrix Mechanics-Dependent Ductal Carcinoma In Situ Progression. <i>Tissue Engineering - Part A</i> , 2021, 27, 454-466.	1.6	3
116	STAT3-induced HLA-FAS1 promotes cell proliferation and stemness characteristics in triple negative breast cancer cells by upregulating TRABD. <i>Bioorganic Chemistry</i> , 2021, 109, 104722.	2.0	10
117	Robust application of new deep learning tools: an experimental study in medical imaging. <i>Multimedia Tools and Applications</i> , 2022, 81, 13289-13317.	2.6	24
118	Silencing of Nek2 suppresses the proliferation, migration and invasion and induces apoptosis of breast cancer cells by regulating ERK/MAPK signaling. <i>Journal of Molecular Histology</i> , 2021, 52, 809-821.	1.0	5
119	Clinical practice guidelines for risk assessment to identify women at high risk of breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021. <i>Chinese Medical Journal</i> , 2021, 134, 1655-1657.	0.9	3
120	Endocrine prevention of breast cancer. <i>Molecular and Cellular Endocrinology</i> , 2021, 530, 111284.	1.6	8
121	Management of breast lesions seen on US images: dual-model radiomics including shear-wave elastography may match performance of expert radiologists. <i>European Journal of Radiology</i> , 2021, 141, 109781.	1.2	15
122	Surgical Excision Versus Neoadjuvant Radiotherapy Followed by Delayed Surgical Excision of Ductal Carcinoma In Situ (NORDIS). <i>Annals of Surgical Oncology</i> , 2021, , 1.	0.7	0
123	Morphological intratumor heterogeneity in ductal carcinoma in situ of the breast. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 33-43.	1.4	1
124	Breast carcinoma in situ: An observational study of tumor subtype, treatment and outcomes. <i>Oncotarget</i> , 2017, 8, 2361-2371.	0.8	8
125	Post-operative radiotherapy is beneficial for T1/T2 triple negative breast cancer patients with four or more positive lymph nodes. <i>Oncotarget</i> , 2017, 8, 42917-42925.	0.8	8
126	Treatment and survival outcomes of lobular carcinoma in situ of the breast: a SEER population based study. <i>Oncotarget</i> , 2017, 8, 103047-103054.	0.8	11
127	Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy. <i>Oncotarget</i> , 2016, 7, 32566-32578.	0.8	27
128	Selective Photodynamic Effects on Breast Cancer Cells Provided by p123 Pluronic®- Based Nanoparticles Modulating Hypericin Delivery. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2020, 20, 1352-1367.	0.9	13
129	Evaluation of the Quadri-Planes Method in Computer-Aided Diagnosis of Breast Lesions by Ultrasonography: Prospective Single-Center Study. <i>JMIR Medical Informatics</i> , 2020, 8, e18251.	1.3	5

#	ARTICLE	IF	CITATIONS
130	An In silico Approach to Identify High Affinity Small Molecule Targeting m-TOR Inhibitors for the Clinical Treatment of Breast Cancer. Asian Pacific Journal of Cancer Prevention, 2019, 20, 1229-1241.	0.5	26
131	Risk factors of breast intraductal lesions in patients without pathological nipple discharge. Molecular and Clinical Oncology, 2020, 13, 38.	0.4	2
132	Immunohistochemical Biomarkers in Ductal Carcinoma <i>>In Situ</i>. Open Journal of Pathology, 2020, 10, 129-146.	0.0	3
133	Large and diffuse ductal carcinoma in situ: potentially lethal subtypes of "preinvasive" disease. International Journal of Clinical Oncology, 2022, 27, 121-130.	1.0	4
134	Occult medullary breast carcinoma in a male. Formosan Journal of Surgery, 2018, 51, 245.	0.1	1
135	Epithelial Hyperplasia. , 2018, , 47-69.		0
137	Whole Breast Invasive Lobular Carcinoma Not Detected Radiographically. Cureus, 2020, 12, e10438.	0.2	1
138	Deep Learning Methods for Mitosis Detection in Breast Cancer Histopathological Images: A Comprehensive Review. Lecture Notes in Computer Science, 2020, , 279-306.	1.0	3
139	Establishing a Program for Young Women at High Risk for Breast Cancer. , 2020, , 35-46.		0
142	Disease evolution and heterogeneity in bilateral breast cancer. American Journal of Cancer Research, 2016, 6, 2611-2630.	1.4	5
143	Overcoming Barriers in Ductal Carcinoma In Situ Management: From Overtreatment to Optimal Treatment. Journal of Clinical Oncology, 2022, 40, 225-230.	0.8	12
144	Histopathological growth distribution of ductal carcinoma in situ: tumor size is not "one size fits all". Gland Surgery, 2022, 11, 307-318.	0.5	1
145	Disparities in Breast Cancer. Obstetrics and Gynecology Clinics of North America, 2022, 49, 149-165.	0.7	32
146	Risk of developing depression among breast cancer patients in Palestine. BMC Cancer, 2022, 22, 295.	1.1	3
147	Vitamin D and Histological Features of Breast Cancer: Preliminary Data from an Observational Retrospective Italian Study. Journal of Personalized Medicine, 2022, 12, 465.	1.1	0
148	LncRNA AY343892 inhibits breast cancer development by positively regulating BRCA1-mediated transcription of PTEN. Histology and Histopathology, 2020, 35, 1171-1180.	0.5	4
149	miR-107 is involved in the regulation of NEDD9-mediated invasion and metastasis in breast cancer. BMC Cancer, 2022, 22, 533.	1.1	5
150	Adherence to cancer prevention recommendations and risk of breast cancer in situ in the United Kingdom Biobank. International Journal of Cancer, 2022, 151, 1674-1683.	2.3	5

#	ARTICLE	IF	CITATIONS
151	Prognostic value of tumor-infiltrating lymphocytes in DCIS: a meta-analysis. BMC Cancer, 2022, 22, .	1.1	1
152	Mass-forming ductal carcinoma in situ: An ultrasonographic and histopathologic correlation study. Pathology Research and Practice, 2022, 237, 154035.	1.0	1
153	Radiopaque tissue transfer and X-ray system <i>versus</i> standard specimen radiography for intraoperative margin assessment in breast-conserving surgery: randomized clinical trial. BJS Open, 2022, 6, .	0.7	0
154	A Scoping Review on the Status of Female Breast Cancer in Asia with a Special Focus on Nepal. Breast Cancer: Targets and Therapy, 0, Volume 14, 229-246.	1.0	4
155	An Application of Generalized Linear Models to Fine Needle Aspiration in Breast Cancer. , 0, 8, 178-184.		0
156	Learning to distinguish progressive and non-progressive ductal carcinoma in situ. Nature Reviews Cancer, 2022, 22, 663-678.	12.8	8
157	Annual cost-savings with the implementation of estrogen-receptor-only testing on Ductal Carcinoma in Situ specimens. American Journal of Surgery, 2022, , .	0.9	0
158	Disparities in Breast Cancer Outcomes and How to Resolve Them. Hematology/Oncology Clinics of North America, 2023, 37, 1-15.	0.9	1
159	Multi-modality radiomics nomogram based on DCE-MRI and ultrasound images for benign and malignant breast lesion classification. Frontiers in Oncology, 0, 12, .	1.3	6
160	Identifying recurrences and metastasis after ductal carcinoma <i>in situ</i> (<i>DCIS</i>) of the breast. Histopathology, 2023, 82, 106-118.	1.6	3
161	Efficacy and safety of endocrine therapy after mastectomy in patients with hormone receptor positive breast ductal carcinoma in situ: Retrospective cohort study. ELife, 0, 12, .	2.8	0
162	Contributions of nanotechnology to the intraductal drug delivery for local treatment and prevention of breast cancer. International Journal of Pharmaceutics, 2023, 635, 122681.	2.6	6
163	Molecular Signatures in Ductal Carcinoma In Situ (DCIS): A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2023, 12, 2036.	1.0	4
164	Research Progress of PCSK9 Function in Tu-mor Microenvironment of Breast Cancer. Medical Diagnosis, 2023, 13, 40-45.	0.0	0
165	De-escalation in DCIS Care. Current Breast Cancer Reports, 2023, 15, 58-68.	0.5	0
166	In situ Raman spectroscopy and machine learning unveil biomolecular alterations in invasive breast cancer. Journal of Biomedical Optics, 2023, 28, .	1.4	4